Table 3.
Comparison of the response to EGFR tyrosine kinase inhibitors between target lesions and pleural effusions in patients with EGFR MT-MPE
|
EGFR MT in LA-MPE (n=26) |
p-value | ||
|---|---|---|---|
| Target lesions | Pleural effusion | ||
| Best overall response | |||
| CR | 0 | 4 (15.4) | 0.007 |
| PR | 23 (88.5) | 12 (46.2) | |
| SD | 1 (3.8) | 3 (11.5) | |
| PD | 2 (7.7) | 7 (26.9) | |
| Objective response | 23 (88.5) | 16 (61.5) | 0.026 |
Values are presented as number (%). EGFR, epidermal growth factor receptor; MPE, malignant pleural effusion; MT, mutant type; LA-MPE, lung adenocarcinoma-associated MPE; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.